Category Archives: Metrics

Even the $100K/yr drugs don’t much work

Advocates for Bayh-Dole make a great deal over the number of drugs that involve university patents that have been approved since the passage of the Bayh-Dole Act. One of their measures is the number of drugs that have been developed. … Continue reading

Posted in Bayh-Dole, Bozonet, Metrics | Leave a comment

Taking Apart APLU’s Talking Points on Bayh-Dole, 4

One more bit about Bayh-Dole in the APLU Talking Points: Before 1980, fewer than 250 patents were issued to U.S. universities annually; discoveries were rarely commercialized for the public’s benefit. By contrast, according to a recent survey by the Association … Continue reading

Posted in Bayh-Dole, Bozonet, History, Metrics | Leave a comment

Lower drug development costs than industry reports–shock!

At the SciScip discussion group notice has been given to an article published in September 2017 in JAMA that has determined the median cost to develop a new cancer drug at $648m, much lower than the pharmaceutical industry reports for … Continue reading

Posted in Commons, Metrics, Policy, Technology Transfer | Leave a comment

Vice presidents for research beg for Directive 10-289.

Here’s a bit from the APLU/AAU fakographic on university technology transfer: And here’s a bit from “‘Miracle machine of U.S. innovation is in danger,” a new op/ed by Kelvin Droegemeier and Daniel Reed. Droegemeier is the vice president for research at … Continue reading

Posted in Bad Science, Metrics, Sponsored Research, Technology Transfer | Leave a comment

UW startups for FY2013 four years later, 1

In 2014, Research Enterprise ran a series of articles on the fake startup metrics at the University of Washington: Only 1 University of Washington Startup for FY 2014 4 Not 17 University of Washington Startups in FY13 Faked Metrics in … Continue reading

Posted in Metrics, Sponsored Research, Startups | Leave a comment

Getting at the truth about Bayh-Dole’s impact, Part 5

Now we get to the crunch of Catherine Kirby’s blog article–published at a Rice University web site for entrepreneurship–with the section “Did the Bill Work?” Since the passage of the Bayh-Dole Act, more than 5,000 new companies have formed from federally … Continue reading

Posted in Bayh-Dole, Metrics, Policy | 1 Comment

Getting at the truth about Bayh-Dole’s impact, Part 1

Last December Catherine Kirby, a student at Rice University, posted “The True Impact of the Bayh-Dole Act” at the McNair Institute for Entrepreneurship and Innovation. Her article got called out in a tweet by Daniel Garisto as an instance of … Continue reading

Posted in Bayh-Dole, Metrics, Policy | Leave a comment

Government Interest Patent Activity 1976 to 2016, Part 4

In a portfolio model, 1 invention in 200 becoming a commercial product is acceptable, if the 1 is a big hit. In an agent model, 1 in 200 is unacceptable and borders on malpractice or fraud unless inventors willingly turn … Continue reading

Posted in Bayh-Dole, History, Innovation, Metrics, Policy, Technology Transfer | Leave a comment

Government Interest Patent Activity 1976 to 2016, Part 3

With this context, let’s return to our patent activity graphs. University and nonprofit patents with a government interest have grown from 10% of all patents citing a government interest to over 50%. This level of activity leveled off around 1998 … Continue reading

Posted in Bayh-Dole, History, IP, Metrics | Leave a comment

Government Interest Patent Activity 1976 to 2016, Part 2

Let’s turn to Research Corporation now. For decades, Research Corporation was the dominant invention management broker for universities. Even where universities created research foundations to manage inventions, those foundations often contracted with Research Corporation to do the actual patent work. … Continue reading

Posted in Bayh-Dole, History, IP, Metrics | Leave a comment